Dr Alice M Jackson (University of Glasgow, Glasgow, UK) discusses the findings from a DAPA-HF sub-analysis. The analysis focused on dapaglifozin and its diuretic use in patients with heart failure and reduced ejection fraction (HFrEF).
Can you briefly summarise the DAPA-HF trial?
What was the rationale of this sub-analysis and what were its aims?
What was the design of the trial and the analysis?
What were your findings?
Have these findings elucidated the mechanism of SGLT2 inhibitors?
What are the take-away messages from the sub-analysis?
Recorded remotely from Glasgow, 2020.
Interviewer: Mirjam Boros
Recording Editor: Natascha Wienand